

IN THE CLAIMS

Claims 1-24. (Canceled)

Claims 25-30 (Previously Canceled)

31. (Previously Canceled)

32. (Canceled)

33. (Canceled)

34. (Previously Canceled)

35. (Previously Canceled)

36. (Previously Amended) An isolated heterodimeric or multimeric soluble receptor complex comprising soluble receptor subunits, wherein at least one of soluble receptor subunits comprises a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6, and further comprising a soluble Class I cytokine receptor polypeptide.

37. (Previously Amended) The isolated heterodimeric or multimeric soluble receptor complex according to claim 36, further comprising a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4).

Claims 38-47. (Canceled)

48. (Previously Added) An isolated heterodimeric receptor complex comprising two soluble receptor subunits, wherein the first soluble receptor subunit consists of a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6, and the second receptor subunit consists of a soluble receptor polypeptide comprising soluble IL-2R γ receptor polypeptide (SEQ ID NO:4).

49. (Previously Amended) The isolated heterodimeric receptor complex according to claim 48, wherein the heterodimeric receptor complex binds a ligand comprising a polypeptide of SEQ ID NO:10, or antagonizes the ligand activity.

50. (Previously Amended) The isolated heterodimeric receptor complex according to claim 48, wherein at least one of the soluble receptor subunits further comprises an affinity tag, label, chemical moiety, toxin, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain.

51. (Previously Amended) The isolated heterodimeric or multimeric receptor soluble complex according to claim 36, wherein the soluble receptor complex further comprises an affinity tag, label, chemical moiety, toxin, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain.

52. (Canceled)

Claims 53-60. (Canceled)

61. (Previously Added) An isolated heterodimeric receptor complex consisting of two soluble receptor subunits, wherein the first soluble receptor subunit consists of a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6, and the second receptor subunit consists of a soluble receptor polypeptide comprising soluble IL-2R γ receptor polypeptide (SEQ ID NO:4).

62. (Previously Amended) The isolated heterodimeric receptor complex according to claim 61, wherein the heterodimeric receptor complex binds a ligand comprising a polypeptide of SEQ ID NO:10 or antagonizes the ligand activity.

63. (Previously Amended) The isolated heterodimeric receptor complex according to claim 61, wherein at least one of the soluble receptor subunits further comprises an affinity tag, label, chemical moiety, toxin, biotin/avidin label, radionuclide, enzyme, substrate,

cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain.

64. (Previously Amended) The isolated heterodimeric receptor complex according to claim 61, wherein at least one of the soluble receptor subunits further comprises a transmembrane domain.

65. (Previously Amended) The isolated heterodimeric receptor complex according to claim 64, wherein the transmembrane domain is from a Class I cytokine receptor.

66. (Previously Amended) The isolated heterodimeric receptor complex according to claim 61, wherein at least one of the soluble receptor subunits further comprises a transmembrane domain, and an intracellular domain from a cytokine receptor.

67. (Previously Amended) The isolated heterodimeric receptor complex according to claim 66, wherein the intracellular domain is from a Class I cytokine receptor.

68. (Previously Amended) The isolated heterodimeric receptor complex according to claim 61, wherein both of the soluble receptor subunits further comprise a transmembrane domain.

69. (Previously Amended) The isolated heterodimeric receptor complex according to claim 68, wherein the transmembrane domain is from a Class I cytokine receptor.

70. (Previously Amended) The isolated heterodimeric receptor complex according to claim 61, wherein both of the soluble receptor subunits further comprise a transmembrane domain, and an intracellular domain from a cytokine receptor.

71. (Previously Amended) The isolated heterodimeric receptor complex according to claim 70, wherein the intracellular domain is from a Class I cytokine receptor.

72. (Previously Added) The isolated heterodimeric or multimeric soluble receptor complex comprising soluble receptor subunits according to claim 36, wherein at least one of soluble receptor subunits comprises a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6, and wherein at least one other of the soluble receptor subunits comprises a soluble receptor polypeptide comprising a Class I cytokine receptor polypeptide.

73. (Previously Added) The isolated heterodimeric or multimeric soluble receptor complex according to claim 72, wherein the Class I cytokine receptor polypeptide comprises a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4).

74. (Previously Added) The isolated heterodimeric or multimeric soluble receptor complex according to claim 72, wherein the heterodimeric or multimeric soluble receptor complex binds a ligand comprising a polypeptide of SEQ ID NO:10, or antagonizes the ligand activity.

75. (Previously Added) The isolated heterodimeric or multimeric soluble receptor complex according to claim 72, wherein at least one of the soluble receptor subunits further comprises an affinity tag, label, chemical moiety, toxin, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain.